Email updates

Keep up to date with the latest news and content from BMC Pharmacology and BioMed Central.

This article is part of the supplement: 15th Scientific Symposium of the Austrian Pharmacological Society (APHAR)

Open Access Meeting abstract

Regulating and regulated role of the orphanin FQ/nociceptin system

Kornélia Tekes1*, Mónika Hantos2, Péter Szegi1 and György Csaba3

Author Affiliations

1 Department of Pharmacodynamics, Semmelweis University, 1089 Budapest, Hungary

2 Department of Pharmacy Administration, Semmelweis University, 1092 Budapest, Hungary

3 Department of Genetics, Cell and Immunobiology, Semmelweis University, 1089 Budapest, Hungary

For all author emails, please log on.

BMC Pharmacology 2009, 9(Suppl 2):A46  doi:10.1186/1471-2210-9-S2-A46

The electronic version of this article is the complete one and can be found online at:

Published:12 November 2009

© 2009 Tekes et al; licensee BioMed Central Ltd.


There is a permanent need for improvement in effective pain management that calls for implication of recent advances in the understanding of endogenous morphine-like substances. Using the technique of ''reverse physiology'' identification of an orphan, opioid-receptor-like 1 receptor (ORL1, recently named as OP4/NOP), and isolation of its endogenous agonist orphanin FQ/nociceptin (NC) opened a new era in opioid pharmacology. In recognition of the involvement of NOP-NC system in a wide range of physiological, and pathophysiological processes, the nociceptinergic system is considered an important new target for drug development in pain control, morphine-withdrawal, anxiety, depression, cognitive impairment, body mass control, cough suppression, hypertension, heart failure and ischemic brain injury.


We conceptionalized that elucidation of (patho)physiological conditions/human disorders with changes in endogenous levels of NC can give significant contribution to drug targeting. [125I]NC-RIA and HPLC methods were used for measurements.


In Wistar rats both in the central nervous system (CSF) and the periphery (blood plasma) NC levels reached the adult level by the age of 12 weeks. Plasticity of unmatured NOP receptors was evidenced in neonatal hormonal imprinting studies with NC. In patients with chronic liver disorders of different etiology (Wilson's disease, primary biliary cirrhosis) plasma NC was found to be elevated, and extremely high levels were observed in hepatocellular carcinoma patients compared to age-matched healthy controls. The functional role of circulating NC in primary neurovascular headaches (migraine and cluster headache patients) was also evidenced. Plasma NC levels in acute stroke and transient ischemic attack patients were found to be elevated compared to healthy controls; however, significantly lower NC levels were observed in atherosclerotic patients with chronic limb ischemia in both the plasma and blood vessels.


The observed changes in endogenous NC levels designate the NOP-NC system as a potential new target in therapy.


This work was supported by a grant of the Hungarian Ministry of Health (ETT 353/2006).